{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:16:21Z","timestamp":1787991381197,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022889","name":"Universidad Nacional Toribio Rodr\u00edguez de Mendoza de Amazonas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100308","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:57:16Z","timestamp":1784962636000},"page":"100308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4075-9049","authenticated-orcid":false,"given":"Victor J.","family":"Vera Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10431","key":"10.1016\/j.obpill.2026.100308_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","year":"2024","journal-title":"Lancet"},{"issue":"10481","key":"10.1016\/j.obpill.2026.100308_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.obpill.2026.100308_bib4","article-title":"Consensus on pharmacological treatment of obesity in Latin America","volume":"25","author":"Cappelletti","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2026.100308_bib5","article-title":"Prevalence of obesity according to body mass index, waist circumference, and waist-to-height ratio in Peru: a systematic review and meta-analysis","volume":"13","author":"V\u00e1squez-Romero","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2026.100308_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.12688\/wellcomeopenres.19498.4","article-title":"Eligibility for obesity management in Peru: analysis of National Health Surveys from 2014 to 2022","volume":"8","author":"Bernabe-Ortiz","year":"2024","journal-title":"Wellcome Open Res"},{"issue":"3","key":"10.1016\/j.obpill.2026.100308_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.obpill.2026.100308_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.obpill.2026.100308_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.obpill.2026.100308_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100308_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.obpill.2026.100308_bib12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.obpill.2026.100308_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3474","article-title":"Estimated sustainable cost-based prices for diabetes medicines","volume":"7","author":"Barber","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.obpill.2026.100308_bib15","series-title":"OECD Reviews of Health Systems: peru 2025","year":"2025"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13098-025-01844-z","article-title":"Prevalence of diabetes and prediabetes in Peru: a systematic review and meta-analysis","volume":"17","author":"Vera-Ponce","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"9596","key":"10.1016\/j.obpill.2026.100308_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2026.100308_bib18","series-title":"Technical data sheet: demographic and Family Health Survey - ENDES","year":"2024"},{"issue":"12","key":"10.1016\/j.obpill.2026.100308_bib19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.obpill.2026.100308_bib20","series-title":"Ministerial resolution no. 633-2023-MINSA. Technical document: national single list of essential medicines for the health sector","year":"2023"},{"key":"10.1016\/j.obpill.2026.100308_bib21","series-title":"Ministerial resolution no. 182-2025-MINSA. Complementary list of medicines for the treatment of type 2 diabetes mellitus and arterial hypertension to the National Single List of Essential Medicines for the Health Sector","year":"2025"},{"key":"10.1016\/j.obpill.2026.100308_bib22","series-title":"Heart failure, or diabetic nephropathy","article-title":"Short HTA Review No. 07-2024. Dapagliflozin 10 mg, empagliflozin 10 mg and 25 mg tablet: treatment of type 2 diabetes mellitus in adult patients with established cardiovascular disease","year":"2024"},{"key":"10.1016\/j.obpill.2026.100308_bib23","series-title":"FARMAMINSA Surco 2. Price list February 2026. Information as of 09\/02\/2026","year":"2026"},{"key":"10.1016\/j.obpill.2026.100308_bib24","series-title":"Efficacy and safety of empagliflozin plus tolerated medical therapy for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction","year":"2024"},{"key":"10.1016\/j.obpill.2026.100308_bib25","unstructured":"Directorate General of Medicines, Supplies and Drugs (DIGEMID). Technical data sheet: Saxenda 6 mg\/mL solution for injection, liraglutide. Lima: Ministry of Health."},{"key":"10.1016\/j.obpill.2026.100308_bib26","unstructured":"Inkafarma. Saxenda 6 mg\/mL solution for injection. Regular price reported in web query: S\/259.90 per unit. Peru; query conducted in May 2026."},{"key":"10.1016\/j.obpill.2026.100308_bib27","series-title":"Preliminary health technology assessment opinion no. 006-DETS-IETSI-2023. Efficacy and safety of naltrexone\/bupropion in adult patients with obesity who persist without weight loss after six months of nutritional therapy and physical activity","year":"2023"},{"key":"10.1016\/j.obpill.2026.100308_bib29","series-title":"Preliminary health technology assessment opinion no. 005-DETS-IETSI-2023. Efficacy and safety of phentermine\/topiramate in adult patients with obesity who persist without weight loss after six months of nutritional therapy and physical activity","year":"2023"},{"key":"10.1016\/j.obpill.2026.100308_bib30","unstructured":"Direcci\u00f3n General de Medicamentos, Insumos y Drogas (DIGEMID). Wegovy (semaglutide), strengths 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, solution for injection in pre-filled pen: technical sheet. Version V01. Lima: Ministry of Health of Peru. Available from:: https:\/\/www.digemid.minsa.gob.pe\/Archivos\/FichasTecnicas\/Biologicos\/FT_PB_BE01463_V01.pdf. Accessed July 20, 2026."},{"issue":"2","key":"10.1016\/j.obpill.2026.100308_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib42","first-page":"128","article-title":"Cost-effectiveness of semaglutide in patients with obesity and cardiovascular disease","volume":"41","author":"Rennert-May","year":"2025","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100308_bib43","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"issue":"9","key":"10.1016\/j.obpill.2026.100308_bib44","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"1","key":"10.1016\/j.obpill.2026.100308_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40545-022-00481-5","article-title":"Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru","volume":"15","author":"Tenorio-Mucha","year":"2022","journal-title":"J Pharm Policy Pract"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:44Z","timestamp":1787988644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S2667368126000641"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100308","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100308"}}